Business Wire

CA-CONVIVA

20.10.2021 20:02:05 CEST | Business Wire | Press release

Share
Conviva Announces Streaming Platform Expansion Solving Audience Measurement Challenges Globally

Conviva , the continuous measurement platform for streaming media, today announces the availability of its technology and real-time data to enable end-to-end advertising audience measurement for its publisher customers and their ecosystem partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005928/en/

Conviva’s global streaming audience measurement technology promises to deliver unique, innovative, and industry-changing solutions based on:

Session-level and census-level measurement

Antiquated third-party web technologies like beacons, logs, pixels or outdated and inaccurate panel methodologies are incapable of dealing with today’s complex device fragmentation. Conviva’s Stream Sensor™ provides continuous collection of every single session using standardized data collection and processing techniques for both session-level and census-level comprehensiveness. This provides a foundation of complete, comprehensive, uniform data that the entire ecosystem can rely on for accurate audience measurement, by eliminating inaccuracies within statistical inferences.

Future-proofed identity

Identity, a necessary pillar for accurate advertising audience measurement, is increasingly unstable due to privacy-regulations, third-party interference, and the rapid growth of anonymized ad-supported viewership. Conviva’s Stream ID™ provides consistent, persistent, accurate identity solutions using the best available first-party data possible, while still accommodating consumer choice and privacy regulations globally.

Ecosystem interoperability

In order to operate effectively in the complex world of audience measurement, content syndication, and cross-platform measurement, publishers must be able to activate their streaming data and audience with multiple ecosystem partners. Conviva’s platform expansion supplying Stream ID, and the Stream Sensor data it carries, are built using a common identity model that creates ecosystem interoperability, from both content partners and ecosystem activation destinations.

Publisher control

For the first time in the history of digital media, premium publishers are now in full control of their streaming data and audience, no longer relying on ‘currency tax’ vendors. This will help the premium publisher ecosystem compete effectively against the hegemony of walled gardens by giving advertisers the audience and context they need to address brand safety concerns.

Conviva certification

Conviva is fully committed to participating in the complete audit and accreditation processes including the Media Ratings Council (MRC) in the U.S. and other relevant industry auditing bodies globally, to certify new census-level standards that surpass any statistical inference accuracy certifications. This vital step ensures that data collection and reporting standards are upheld, to provide brands and agencies confidence in the accuracy of Conviva's audience measurement and reporting.

Conviva’s evolution is being led by the company’s recently-appointed President and CEO, Keith Zubchevich, a streaming industry veteran with more than a decade at Conviva. In his previous role as Chief Strategy Officer, Zubchevich worked closely with customers to understand their pain points and drive Conviva’s innovation to solve them, relationships that continue to inform his strategy as CEO.

“Today Conviva is already underfoot with premium publishers, collecting 3 trillion streaming events daily with insight into 500 million unique viewers globally,” comments Zubchevich. “The fact is Conviva has already solved for the incredibly complex challenge of standardized, census-level streaming measurement and is now working with our premium publishers and their ecosystem partners to introduce a new standard of audience measurement and quality to the global industry, to enable long-overdue innovation and change.”

About Conviva

Conviva is the census, continuous measurement and engagement platform for streaming media. Powered by our patented Stream Sensor™ and Stream ID™, our real-time platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like CCTV, DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today our platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. Conviva ensures digital businesses of all sizes can stream better—every stream, every screen, every second. To learn more, visit www.conviva.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Philip Morris International and Maestro Andrea Bocelli Present “Believe. Further”29.6.2026 12:00:00 CEST | Press release

A new platform for dialogue on progress, reflecting a mutual commitment to advancing positive change Philip Morris International (PMI) (NYSE: PM) and Maestro Andrea Bocelli today presented “Believe. Further”, a multi-year platform designed to engage audiences in a broader conversation on progress and positive change. The launch took place at the Torre dell’Arsenale in Venice, where heritage and forward movement meet, a fitting setting for two voices on a similar path. What do you do when the world has already decided what you are? “Believe. Further” begins from that question. It is built around a shared belief in progress and a shared conviction in transformation. At a time when science and technology allow better choices, it brings together two voices that, independently and in parallel, are undergoing a change in motion, and invites the beginning of a different conversation with society at large. Maestro Bocelli’s journey has been defined by belief. From the beginnings of his career

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye